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Abstract
Dietary immunoglobulin concentrates prepared from animal plasma can modulate the
immune response of gut-associated lymphoid tissue (GALT). Previous studies have
revealed that supplementation with serum-derived bovine immunoglobulin/protein isolate
(SBI) ameliorates colonic barrier alterations in the mdr1a-/- genetic mouse model of IBD.
Here, we examine the effects of SBI on mucosal inflammation in mdr1a-/- mice that sponta-
neously develop colitis. Wild type (WT) mice and mice lacking the mdr1a gene (KO) were
fed diets supplemented with either SBI (2% w/w) or milk proteins (Control diet), from day 21
(weaning) until day 56. Leucocytes in mesenteric lymph nodes (MLN) and in lamina propria
were determined, as was mucosal cytokine production. Neutrophil recruitment and activa-
tion in MLN and lamina propria of KO mice were increased, but were significantly reduced in
both by SBI supplementation (p < 0.05). The increased neutrophil recruitment and activation
observed in KOmice correlated with increased colon oxidative stress (p < 0.05) and SBI
supplementation reduced this variable (p < 0.05). The Tact/Treg lymphocyte ratios in MLN
and lamina propria were also increased in KO animals, but SBI prevented these changes
(both p < 0.05). In the colon of KO mice, there was an increased production of mucosal pro-
inflammatory cytokines such as IL-2 (2-fold), IL-6 (26-fold) and IL-17 (19-fold), and of che-
mokines MIP-1β (4.5-fold) and MCP-1 (7.2-fold). These effects were significantly prevented
by SBI (p < 0.05). SBI also significantly increased TGF-β secretion in the colon mucosa,
suggesting a role of this anti-inflammatory cytokine in the modulation of GALT and the
reduction of the severity of the inflammatory response during the onset of colitis.
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Introduction
Inflammatory bowel diseases (IBD) are characterized by diffuse chronic intestinal inflamma-
tion, typically involving neutrophil infiltration, the production of inflammatory mediators, and
alterations in the colon barrier that are usually life-long in nature [1]. The etiopathogenesis of
IBD has not been clearly elucidated, but it involves a complex interplay of genetic, environmen-
tal, microbial, and immune factors, which alter the barrier properties of the mucous and epi-
thelial layers. This allows luminal toxins and antigens to penetrate the mucosa and challenge
the gut-associated lymphoid tissue (GALT). Dysregulation of gut immunity causes an overpro-
duction of pro-inflammatory cytokines and trafficking of effector leukocytes into the intestinal
mucosa, thus leading to an uncontrolled intestinal inflammation [2].
The treatment of IBD is mainly pharmacological and involves anti-inflammatory drugs and
agents that reduce the symptoms associated with IBD [3]. These therapies ameliorate IBD, but
their use for long periods of time may result in adverse side effects, including immune suppres-
sion [4]. For these reasons, nutrition emerges as an alternative to drug therapies, and food
choice has become a promising tool for the treatment and prevention of IBD [5]. In this
respect, dietary supplementation with specific macro- and micronutrients such as omega-3
fatty acids [6], prebiotics and probiotics [7] or polyphenolic compounds [8] has been shown to
have some effectiveness. Milk-derived supplements have also been evaluated for the treatment
of inflammatory syndromes. For example, bovine colostrum improved clinical symptoms of
colorectal inflammation in a well-established mouse model of DSS-induced colitis [9], and lac-
toferrin [10] and glycomacropeptide from bovine milk [11] demonstrated anti-inflammatory
properties in rodent models of colitis. Animal plasma-derived proteins also have anti-inflam-
matory effects and are candidates for use in the management of IBD. Results from our labora-
tory show that dietary supplementation with porcine spray-dried plasma proteins, either full
plasma (spray-dried plasma, SDP) or an immunoglobulin-rich concentrate (IC), can regulate
GALT-mediated immune responses in models of acute intestinal inflammation. In the small
intestine, both SDP and IC reduce the activation of Th lymphocytes [12], prevent the release of
pro-inflammatory cytokines [13] and restore impaired barrier function [14], in a rat model of
intestinal inflammation induced by the S. aureus enterotoxin B.
Another supplement that has been extensively studied in animal models is serum-derived
bovine immunoglobulin/protein isolate (SBI), which contains over 90% protein, more than
50% of which consists of immunoglobulins, mainly IgG. SBI reduces inflammatory markers
and tissue damage in mice models of colitis [15] and mucositis [16], and it has been reported to
be effective in the management of enteropathy associated with diarrhea-predominant IBS and
HIV infection [17]. Clinical trials in which SBI was administered to patients with irritable
bowel syndrome obtained some improvements in symptoms, consistent with a limiting effect
of SBI on cytokine production in the inflamed intestinal mucosa [18], through a mechanism
involving bacterial antigen binding in the intestinal lumen [19].
In this study, the effects of SBI administration on colitis were assessed in mice lacking the
mdr1 gene. This gene encodes P-glycoprotein 170 (P-gp), a membrane transporter that actively
pumps toxins and xenobiotics back to the lumen and which is highly expressed in the gastroin-
testinal tract [20]. The mdr1a-/- mouse is a good model of colitis because it shows barrier alter-
ations and inflammation with a location and characteristics similar to human IBD [21], and in
particular to Crohn’s disease (CD). Moreover, in inflamed mdr1a-/- mice, changes in the
expression of genes coding for pro-inflammatory markers and detoxification enzymes are simi-
lar to those observed in human IBD, further supporting the suitability of this model for pre-
clinical studies [22].
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Using this model, dietary SBI has been shown to attenuate barrier alterations in the colon,
reduce the expression of pro-inflammatory cytokines such as TNF-α and IFN-γ, and the
expression of iNOS [15], all of which are involved in the regulation of mucosal integrity. In
view of these effects, it was decided to expand the study of the immunomodulatory functions
of SBI in mdr1a-/- mice by analyzing the profile of T-lymphocyte populations and the expres-
sion of other pro-inflammatory mediators and anti-inflammatory cytokines in mesenteric
lymph nodes (MLN) and the lamina propria of the colon.
Material and Methods
Animals and diets
FVB wild type mice (WT) and mdr1a-/- mice (FVB.129P2-Abcb1atm 1BorN7; KO) were pur-
chased from Taconic (Germantown, NY). A stable colony was obtained and maintained in the
specific pathogen free (SPF) area of the Animal Experimentation Service of the Barcelona Sci-
ence Park (BSP), University of Barcelona. Animals were kept under stable temperature and
humidity conditions, with a 12 h:12 h light/dark cycle. Mice were housed in polycarbonate
microisolator cages contained in individual ventilated racks under barrier conditions. All pro-
tocols used in this study were approved by the Ethics Committee for Animal Experimentation
of the BSP (Permit number: P03-R1-08). In accordance with our institution’s guidelines, the
number of animals used in our study was kept as low as possible, usually 7–8 mice per group,
and treated under blind conditions. Special care was taken to prevent infection with environ-
mental Helicobacter bacteria and animals were checked to ensure they were Helicobacter free
using sentinel mice.
Serum-derived bovine immunoglobulins were obtained from edible bovine blood collected
at USDA inspected slaughterhouses, therefore is a product that contains a range of immuno-
globulins with broad spectrum of antibodies against a variety pathogens and antigens, but
doesn’t content specific antibodies developed against particular pathogen or antigen. The
experimental diets were formulated to provide similar amount of energy, protein, fat and car-
bohydrates. They were prepared and irradiated by Harlan Ibérica (Barcelona, Spain), and the
composition is shown in Table 1.
Experimental design
Animals were weaned at 21 d of age and started to consume the experimental diets ad libitum.
They were maintained in the SPF area until d 28, when they were transferred to a conventional
housing area. At 56 d of age, mice were anesthetized by i.p administration of ketamine (90 mg/
Kg) and xilacine (10 mg/kg) followed exsanguination by cardiac puncture. The clinical signs of
colitis were analyzed using the disease activity index (DAI), which scores weight loss, stool con-
sistency and bleeding, as described elsewhere [15].
Morphological study
Colon fragments were washed with PBS and fixed overnight with 4% paraformaldehyde, dehy-
drated in graded ethanol, and embedded in paraffin. Ten μm sections were stained with hema-
toxylin-eosin according to standard protocols. Samples were observed under blind conditions
using an optic Olympus BX41 microscope (Münster, Germany).
Lamina propria cell isolation
Cell isolation was performed as described elsewhere [23]. Briefly, the colon was extracted,
washed and everted. The tissue was then incubated in 10 ml of pre-digestion solution (HBSS
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with 10% FBS, 5 mM EDTA and 1 mMDTT) for 25 min at 37°C in a Thermomixer shaker
(Eppendorf, Hamburg, Germany). The cell suspension was eliminated.
The remaining colon was cut, finely minced, and incubated in RPMI 1640 (Invitrogen,
Carlsbad, CA) containing 5% FBS, penicillin/streptomycin, 10 nM HEPES, 2 mM L-glutamine
and 1500 U/mL collagenase (Invitrogen) at 37°C for 20 min in a Thermomixer shaker.
Cell suspensions were centrifuged at 500g for 10 min at 4°C. The pelleted cells were re-sus-
pended in 40% Percoll in complete RPMI. This cell suspension was then carefully layered over
80% Percoll in complete RPMI medium and centrifuged at 1000g for 20 min at 20°C. The ring
of cells was carefully collected, transferred to a clean tube and centrifuged at 500g for 10 min at
4°C. The pelleted cells were re-suspended in PBS-FBS. Cell number and viability were deter-
mined using acridine orange and ethidium bromide markers.
Mesenteric lymph node cell isolation
The leukocytes fromMLN were isolated as previously described [12]. Cell number and viability
were determined using acridine orange and ethidium bromide markers.
Cell staining
Sample processing was similar to the procedure described previously [24]. Briefly, staining was
performed on 3105 cells. The surface markers were analyzed with primary antibodies conju-
gated to fluorochromes. The antibodies used were: anti-CD45R (clone 30-F11), anti-CD3 (145-
2C11), anti-CD4 (GK1.5), anti-CD25 (PC61.5), anti-Gr1 (Ly-6G; 1A8), anti-CD68 (FA-11),
anti-FoxP3 (FJK-16s) and anti-CD14 (Sa2-8), purchased as fluorescent conjugates from BD
Biosciences (Franklin Lakes, NJ) or eBioscience (San Diego, CA). Results were analyzed using
the Flowjo software package (Treestar Inc., Ashland, OR).
Table 1. Composition of the experimental diets.
INGREDIENT Control (g/kg) SBI diet (g/kg)
SBI† – 20
Corn starch 199.3 254.8
Skim milk 530.7 430
Sugar 94.5 100
Soybean oil 70 70
Cellulose 50 50
AIN-93 GM‡ 35 35
AIN-93 VX‡ 15 15
DL-methionine 2.5 2.2
Choline bitartrate 3.0 3.0
Total 1000 1000
†SBI: Serum-derived bovine immunoglobulin contains > 90% protein, over 50% of which is IgG.
Manufactured according to FDA bulk pharmaceutical ingredient standards by EnteraHealth (Cary, NC)
under the commercial name EnteraGam™.
‡Provided by Harlan Ibérica (Barcelona, Spain).
doi:10.1371/journal.pone.0154823.t001
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Cytokine determination
Samples of colon mucosa were homogenized as previously described [13]. IL-2, IL-6, IL-10, IL-
17, MCP-1 and MIP-1β were measured by Bio-Plex Cytokine Assay™ (Bio-Rad, Hercules, CA)
and TGF-β by TGFβ1 Emax1 ImmunoAssay System (Promega Corporation, Madison, WI).
Determination of oxidative stress in colon mucosa
Hydrogen peroxide was measured as an indicator of oxidative stress and it was quantified
using the Hydrogen Peroxide Assay Kit (Sigma-Aldrich, St. Louis, MI) according to the manu-
facturer’s instructions.
Real-time PCR analysis
RNA extraction and reverse transcription were carried out as described previously [15]. Total
RNA was retrotranscribed using an iScript cDNA Synthesis Kit (Bio-Rad). The primers used to
detect intercellular adhesion molecule-1 (ICAM-1), catalase and GAPDH were as follows:
ICAM-1 forward CAGTCCGCTGTGCTTTGAGAA and reverse GAGGTCTCAGCTCCACACTCT;
catalase forward TTTCACTGACGAGATGGCAC and reverse GTGGGTGACCTCAAAGTATCC;
and GAPDH forward GGCATTGCTCTCAATGACAA and reverse CCCTGTTGCTGTAGCCGTA
T. Real-time PCR was performed on a MiniOpticon Real-Time PCR System (Bio-Rad). Sam-
ples were tested in duplicate and the average values were used for quantification, which was
carried out by the 2ΔΔCT method [25]. Product fidelity was confirmed by melt-curve analysis.
Statistical analysis
The data from the experiments are presented as the mean ± SEM. Mean values of normally dis-
tributed data were compared using one-way ANOVA followed by a LSM post hoc test. Recruit-
ment of activated neutrophils and oxidative stress were correlated by Pearson coefficient.
Statistical tests were performed using SPSS-17.0 software (IBM, Armonk, NY). Differences
were considered significant at p< 0.05.
Results
Scores for the disease activity index (DAI), used to quantify the clinical signs of colitis at the
end of the experimental period, were three-fold higher in mdr1-/- mice than in WTmice, and
SBI administration tended to induce a reduction in DAI scores, as reported elsewhere [15].
SBI supplementation improves body weight gain in mdr1a-/- mice
The growth rate of KO mice was lower than that of WT mice, as shown in Fig 1A (p< 0.05).
Dietary SBI increased body weight throughout the experimental period (comparison of control
KO and KO-SBI groups at day 45 and 55 resulted in p = 0.07 and p = 0.06 values, respectively).
At the end of the experimental period, there was a significant effect of SBI supplementation on
weight gain in both WT and KOmice (p< 0.05; Fig 1B).
SBI reduces colon infiltration in mdr1a-/- mice
The colons of KO mice were thicker and shorter than those of WT animals (p< 0.001; Fig 1C
and 1D). The differences in colon diameter and wall thickness are clearly evident in the colon
sections shown in Fig 2. SBI supplementation reduced colon weight only in KO mice (p = 0.06;
Fig 1C) and had no effects on colon length. Leukocyte recruitment in mesenteric lymph nodes
(MLN) and in lamina propria were markedly stimulated in KO mice. There was about 3-fold
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PLOS ONE | DOI:10.1371/journal.pone.0154823 May 3, 2016 5 / 15
increase in leukocyte number in MLN, and a 13-fold increase in the lamina propria compart-
ment (all p< 0.001, Fig 3A and 3B; Fig 2). The interaction between dietary treatment and coli-
tis onset was only apparent in the lamina propria, where SBI reduced leukocyte recruitment by
40% (p< 0.001).
The expression of markers that participate in leukocyte recruitment, such as ICAM-1, was
notably increased in colitic mice (Fig 3C) and reduced in part by dietary SBI (p< 0.001). Fur-
thermore, MIP-1β and MCP-1, chemokines involved in leukocyte recruitment into the colon
mucosa, were also strongly stimulated in KO mice (both p< 0.001; Fig 3D and 3E), and SBI
supplementation reduced their concentration in the colon (all p< 0.05).
SBI reduces the activation of innate immunity in mdr1a-/- mice
Neutrophil recruitment in KO mice was also enhanced in MLN (2.7-fold; Fig 4A) and in the
lamina propria (28-fold; Fig 4B), as was the percentage of activated neutrophils (2–3 fold; all
p< 0.001, Fig 4C and 4D). SBI reduced neutrophil counts and the percentage of activated neu-
trophils in MLN (both p< 0.05); however, in the lamina propria, the interaction between coli-
tis onset and SBI supplementation was only observed for neutrophil recruitment (p< 0.001;
Fig 4B).
Another variable used to characterize inflammation was peroxide production and metabo-
lism. KO mice showed an increased concentration of hydrogen peroxide in the colon mucosa
Fig 1. Effects of SBI supplementation on body weight and colon. Panel A shows body weight evolution
of WT and KOmice during the experimental period. Results are expressed as mean ± SEM (n = 7–8
animals). *indicates significant differences betweenWT groups (WT and SBI) and KO groups (KO and
KO-SBI); ǂindicates significant differences between KO and KO-SBI groups, P<0.05. Panel B shows body
weight gain during the experimental period. Panels C and D show the colon weight and length, respectively.
Results are expressed as mean ± SEM (n = 7–8 animals). Means without a common letter differ, p < 0.05.
doi:10.1371/journal.pone.0154823.g001
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and this effect was partially reduced by SBI supplementation (both p< 0.05; Fig 5A). The num-
ber of activated neutrophils that were infiltrated into the lamina propria and peroxide concen-
tration in the colon were well correlated (R2 = 0.9215; p< 0.0001; Fig 5B), indicating that
neutrophils are involved in colitis development. Catalase expression was also strongly stimu-
lated in KO mice and significantly reduced in KO-SBI mice (p< 0.05; Fig 5C).
SBI mitigates the activation of adaptative immunity in mdr1a-/- mice
KOmice showed a considerable increase in Th lymphocyte counts in colon lamina propria,
and this effect was reduced by SBI (p< 0.001 and p< 0.05, respectively; Fig 6A).
Pro-inflammatory cytokines were also analyzed in the colon mucosa. As expected, KO mice
showed a several-fold increase in IL-6 secretion relative to WT mice (p< 0.001, Fig 6B), and
this was reduced by SBI (p< 0.001). KO mice also had an increased IL-2 production
(p< 0.001; Fig 6C), which was attenuated by dietary supplementation (p< 0.005). In addition,
the release of IL-17, a cytokine that mediates recruitment of monocytes and neutrophils to the
site of inflammation [26], was strongly stimulated in the colonic mucosa (p< 0.001; Fig 6D).
The increased production of IL-17 observed in colitic mice was reduced by SBI (p< 0.005). In
contrast, the production of IL-4, a cytokine typically involved in the Th2 immune response,
was not affected by the onset and progression of colitis, and no effect of SBI was observed either
(data not shown).
The percentage of activated lymphocytes in MLN and lamina propria of KO mice was
increased, and this change was partially prevented by SBI supplementation (p< 0.001 and
p< 0.05 respectively; Fig 7A and 7B). The Treg population was increased in the lamina propria
of KO mice (p< 0.01; Fig 7D) and this was not affected by SBI supplementation. Calculation
of the ratio of activated to regulatory Th lymphocytes (the Tact/Treg ratio) showed that this
variable was markedly increased in MLN and lamina propria during the development of colitis
Fig 2. Colon histology.Representative images obtained from the colon of WT, SBI, KO and KO-SBI mice.
Upper row, 10x magnification; lower row, 20x magnification.
doi:10.1371/journal.pone.0154823.g002
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(all p< 0.005, Fig 7E and 7F), as a result of an increased proportion of Tact lymphocytes. This
change was reverted by dietary SBI (p< 0.05), indicating lower immune activation.
Lastly, the production of mucosal anti-inflammatory cytokines was also studied. Distinct
effects on IL-10 and TGF-β were observed. The progress of colitis did not affect TGF-β secre-
tion (Fig 8A), but IL-10 production was markedly increased in KO mice (p< 0.001; Fig 8B).
The effects of dietary supplementation with SBI also differed, observing TGF-β production
(p< 0.005) without affecting the IL-10 balance.
Discussion
Mdr1a-/- mice are prone to spontaneously develop severe intestinal inflammation, with clinical
and histopathological manifestations that are phenotypically similar to human IBD [27;8].
Recently, alterations in colon barrier function and increased expression of the pro-inflamma-
tory cytokines TNF-α and IFN-γ have been reported in mdr1a KO mice [15], and it has also
been shown that dietary supplementation with SBI reduces the expression of pro-inflammatory
markers and prevents barrier deterioration. In the present study, we further characterize muco-
sal GALT during progression of the colitis syndrome, and describe how these changes can be
modulated by dietary intervention.
A hallmark of all chronic inflammatory disorders is the rapid recruitment and inappropriate
retention of leukocytes at the site of inflammation [28]. The KO mice used in the present study
Fig 3. Effects of SBI supplementation on cell recruitment. Panels A and B represent leukocyte counts in
mesenteric lymph nodes (MLN) and in the lamina propria of the colon, respectively. Panel C shows the expression of
intercellular adhesion molecule 1 (ICAM-1) in the colon mucosa. Panels D and E indicate the concentration of MIP-1β
and MCP-1 in colon mucosa. Results are expressed as mean ± SEM (n = 7–8 animals). Means without a common
letter differ, p < 0.05.
doi:10.1371/journal.pone.0154823.g003
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Fig 4. Effects of SBI supplementation on neutrophil recruitment and activation. Panels A and B show
neutrophil counts in mesenteric lymph nodes (MLN) and colon lamina propria (LP), respectively. Panels C
and D show the percentage of activated (Act.) neutrophils with respect to the neutrophil population in MLN
and colon LP, respectively. All results are expressed as mean ± SEM (n = 7–8 animals). Means without a
common letter differ, p < 0.05.
doi:10.1371/journal.pone.0154823.g004
Fig 5. Effects of SBI supplementation on oxidative stress. Panel A shows mucosal oxidative stress measured as hydrogen
peroxide concentration in homogenates of colon mucosa. Panel B shows the correlation between infiltrated activated (Act.)
neutrophils and oxidative stress. Panel C indicates the expression of catalase in colon mucosa. Results are expressed as
mean ± SEM (n = 5–6 mice). Means without a common letter differ, p < 0.05.
doi:10.1371/journal.pone.0154823.g005
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showed increased leukocyte recruitment into lamina propria and MLN, which correlated well
with increased expression of TNF-α [15] and of MIP-1β and MCP-1. They also showed
increased ICAM-1 expression, an adhesion molecule that plays an important role in evoking
effective immune responses [29] and which is critical for T cell activation and leukocyte
recruitment to the site of inflammation.
Leukocyte recruitment into the lamina propria was attenuated by SBI. This effect is medi-
ated by two pathways working in parallel: firstly, SBI reduces expression of TNF-α [15], which
is the main regulator of ICAM-1 expression. This enables activated leukocytes to bind endothe-
lial cells via the ICAM-1/integrin signaling pathway, which can then transmigrate into tissues
[30]. Secondly, SBI reduces the expression of MIP-1β and MCP-1, two chemokines involved in
leukocyte recruitment [31] that have been shown to be increased in the intestinal mucosa of
patients with CD [32]. Overexpression of MCP-1 has been reported to induce fibrogenic
responses in mouse colon, due to interactions between T cells and fibroblasts/myofibroblasts
[33].
SBI supplementation reduced the accumulation of activated innate immune cells in both
MLN and lamina propria, and this was correlated with reduced production of MIP-1β and
MCP-1. This effect is noteworthy because chemokines are important mediators for the recruit-
ment and accumulation of neutrophils and macrophages in colitis models [34;35]. Moreover,
the effects on cellular infiltration are important because activated neutrophils and monocytes
produce reactive oxygen species (ROS) and free radicals that increase oxidative stress, which
Fig 6. Effects of SBI supplementation on Th lymphocyte recruitment and cytokine production. Panel A
shows Th lymphocyte counts in the lamina propria (LP) of the colon. Panels B, C and D indicate the
concentration of IL-6, IL-2 and IL-17 in colon mucosa, respectively. Results are expressed as mean ± SEM
(n = 5–6 mice). Means without a common letter differ, p < 0.05.
doi:10.1371/journal.pone.0154823.g006
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may further injure the tissue, as enhanced ROS formation disrupts epithelial cell integrity [36].
SBI supplementation reduced oxidative stress in the colon mucosa and improved the epithelial
barrier function, as already observed elsewhere [15]. The effect of SBI on ROS production is
probably the result of reducing the recruitment of activated innate cells rather than a conse-
quence of increased colon antioxidant capacity. SBI did not affect the expression of antioxidant
enzymes, such as catalase, but it reduced the number of activated neutrophils in the lamina
Fig 7. Effects of SBI supplementation on activated (Act.) and regulatory Th lymphocytes (Treg).
Panels A and B show the percentage of Act. Th lymphocytes in mesenteric lymph nodes (MLN) and in the
lamina propria (LP) of the colon. Panels C and D show the percentage of Treg in MLN and LP. The ratios
between both populations are shown in panels E and F. Results are expressed as mean ± SEM (n = 5–6
mice). Means without a common letter differ, p < 0.05.
doi:10.1371/journal.pone.0154823.g007
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propria of the colon, which in turn will reduce the expression of iNOS in the colon, as previ-
ously shown [15].
Studies using models of IBD have shown that CD4+T cells play a major role in initiating
and shaping the syndrome and that their capacity to extend gut inflammation is largely depen-
dent on the production of distinct cytokine profiles [37]. In the mdr1a KO mouse model, the
percentage of activated Th lymphocytes in MLN and in lamina propria was increased, and this
correlated well with the expression of IFN-γ [15] and IL-2 and IL-17 secretion, as described for
IBD [38]. Increased activation of lamina propria T-lymphocytes is a key factor in IBD patho-
genesis, as it leads to unrestrained accumulation of activated lymphocytes that perpetuate
inflammation [39;40;27]. However, production of mucosal IL-4 (a cytokine typically represen-
tative of ulcerative colitis syndrome) was not affected in mdr1 KO mice (data not shown), indi-
cating that the mdr1 KO model may be more representative of the CD syndrome [21].
SBI supplementation reduced the percentage of activated Th lymphocytes in MLN and in
the lamina propria, and this resulted in lower IL-2 and IFN-γ release. This is noteworthy
because there is broad consensus that Th lymphocytes are the most important activated
immune cells involved in IBD pathogenesis [41]. Pathological T cell activation results in a dis-
turbed balance between pro- and anti-inflammatory cytokines [42]. Moreover, SBI supplemen-
tation reduced IL-17 secretion in colon mucosa of mdr1a KO mice. This effect may be
clinically relevant because the inflammation profile that has been described for CD is charac-
terized by IL-17 activation that further stimulates the secretion of pro-inflammatory cytokines
in a self-sustaining cycle [43]. SBI stimulated the production of mucosal TGF-β and this was
inversely correlated with IL-17 production, indicating that SBI-dependent changes in cellular
and cytokine pro-inflammatory profiles in mdr1a KO mice are mediated by TGF-β rather than
by IL-10. Taken together, the present results indicate that CD4+T cells play an important role
in shaping the immune response during development of colitis and that attenuation of Th1
and Th17 responses by SBI could represent a significant step forward in the treatment of IBD.
This is especially so in the case of CD, given that increased expression of Th1 and Th17 in this
syndrome is well documented [2].
The homeostatic condition of the intestinal mucosa is a state of controlled inflammation char-
acterized by a balance between protective immunity and tolerance to self-antigen and commen-
sal bacteria [44]. Tolerance is maintained by Tregs, a population of CD4+ T cells that controls
immune responses by inhibiting the proliferative and effector functions of other T cells. There is
evidence showing that the inflammation that characterizes IBDmay be caused by the loss of
homeostatic steady-state between Treg (CD4+ CD25high Foxp3+) and pro-inflammatory
Fig 8. Effects of SBI supplementation on TGF-β (A) and IL-10 (B) production in the colon.Results are
expressed as mean ± SEM (n = 5–6 mice). Means without a common letter differ, p < 0.05.
doi:10.1371/journal.pone.0154823.g008
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activated Th cells [45]. Mdr1a KOmice have an increased Tact/Treg ratio in MLN and lamina
propria due to an increase in the Tact population, and SBI partially prevents this change because
it reduces the Tact subpopulation and increases the percentage of Treg lymphocytes. The impor-
tant result is that SBI can reduce the Tact/Treg lymphocyte ratio in both tissues, supporting a
bias toward immune tolerance. This effect of SBI is homeostatic, as it restores the balance
between Treg and Tact lymphocytes that was altered in colitic mice. A similar pattern of
response has been observed in mice models of toxin-induced acute mild intestinal inflammation
[46] and acute lung inflammation [47]. In both cases, the toxin challenge increased the Tact/
Treg ratio and dietary plasma proteins restored the pre-challenge Tact/Treg ratio values. The
importance of these effects lies in the role of Tregs in the suppression of Th effector cells through
the secretion of anti-inflammatory cytokines such as IL-10 and TGF-β [48]. IL-10 reduces Th
cell proliferation and decreases secretion of harmful cytokines, and TGF-β has similar effects on
naïve and already differentiated Th cells [49]. Thus, the suppressant effect of Treg on Tact cells
is important for immune homeostasis in the gastrointestinal tract. SBI supplementation did not
modify the release of IL-10, but it did increase TGF-β production, suggesting that the effects of
SBI on cell activation are mediated by changes in TGF-β production.
In summary, dietary SBI reduced the amount of activated Th lymphocytes and promoted
the presence of regulatory Th cells in mice spontaneously developing colitis; in turn, this
increased TGF-β secretion favored the predominance of an anti-inflammatory immune profile.
This cascade of effects eventually reduces mucosal pro-inflammatory cytokines. The beneficial
effect of SBI on this model suggests a role of serum-derived supplements in the prevention and
amelioration of IBD.
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